scispace - formally typeset
J

Jacques-Olivier Bay

Researcher at University of Auvergne

Publications -  347
Citations -  9485

Jacques-Olivier Bay is an academic researcher from University of Auvergne. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 40, co-authored 311 publications receiving 8184 citations. Previous affiliations of Jacques-Olivier Bay include French Institute of Health and Medical Research.

Papers
More filters
Journal ArticleDOI

Phase II Trial of Weekly Paclitaxel for Unresectable Angiosarcoma: The ANGIOTAX Study

TL;DR: Weekly paclitaxel at the dose schedule used in the current study was well tolerated and demonstrated clinical benefit, and anemia and fatigue were the most frequently reported toxicities.
Journal ArticleDOI

Clinical features and prognostic factors of listeriosis: the MONALISA national prospective cohort study.

Caroline Charlier, +1778 more
TL;DR: Evidence of a significantly reduced survival in patients with neurolisteriosis treated with adjunctive dexamethasone is found, and the time window for fetal losses is determined, which is higher than reported elsewhere.
Journal ArticleDOI

Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial

TL;DR: The toxicity of the temsirolimus and bevacizumab combination was much higher than anticipated and limited treatment continuation over time, and this combination cannot be recommended for first-line treatment in patients with metastatic renal cell carcinoma.
Journal ArticleDOI

Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial.

TL;DR: The Programme Etude Rein Cytokines (PERCY) Quattro trial was designed to evaluate both cytokines for their survival benefit to intermediate prognosis patients, who represent the majority of candidates for these treatments.